To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

February 14, 2019

Today's Rundown

Featured Story

Eagle and Mystic lead AstraZeneca’s cancer clear out 

AstraZeneca has cleared a clutch of cancer programs from its clinical pipeline. The PD-L1 combination trials Eagle and Mystic led the clear out, and the immuno-oncology drugs tested in those studies feature heavily in the earlier-phase cull.

Top Stories

Liver toxicity concerns spike Motif Bio’s iclaprim filing

Motif Bio’s hope of adding to the antibiotic armamentarium for serious bacterial infections has just been dealt a blow by the FDA.

Axovant sends off its small molecule team with an epilepsy drug and $100M in funding commitments

Axovant has spun off its small molecule team into a new company, Arvelle Therapeutics, as it continues its march toward becoming a biotech with a sole focus on gene therapies.

[Sponsored] Invert to Convert: Rethinking Patient Recruitment & Enrollment Strategies

90% of clinical trials will meet their enrollment goals if their original timelines are doubled. WCG breaks down the barriers to ramping up and meeting patient enrollment goals. A new approach addresses root causes and accelerates study timelines by 33%.

5AM, JJDC get in on $42M series A round for cell therapy player Vor Biopharma

The funding will advance Vor's lead asset, an engineered hematopoietic stem cell (HSC) therapy for acute myeloid leukemia, as well as the development of a pipeline of HSC-based treatments for other blood cancers.

Novartis inks 10-target antibody discovery deal with AbCellera

Novartis has struck a deal to apply AbCellera’s antibody discovery capabilities to up to 10 targets. The deal sees Novartis join GlaxoSmithKline, Merck and Pfizer on the list of companies partnered with the antibody discovery shop.

Amgen taps Abilita Bio’s membrane protein technology

Amgen and Abilita Bio have inked a research deal in which Abilita will use its Enabled Membrane Protein platform to help Amgen work to develop drugs for challenging targets.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Resources

[Whitepaper] Better Market Intelligence With Smart Search

It’s never been more challenging to stay on top of trends and innovation shaping the future of healthcare. Discover how AI can help competitive intelligence teams achieve more proactive strategies.

[Webinar] Biostatistics for Non-Statisticians: Understanding Different Types of Analyses and When to Use Each

If commonly used statistical phrases like two-sample t-test, difference in proportions, or hazard ratio intimidate you, join this webinar for an introduction to statistical analyses in clinical trials.

[Whitepaper] Managing Demand Uncertainty in Biologics Production

When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need, factoring in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market and a host of other variables.

[Whitepaper] RTSM/IRT: A Roadmap For Developing Systems That Address Current Frustrations

92% of survey respondents make changes to their RTSM/IRT systems due to study changes. See what else puts a strain on their clinical trials. Download the Research Whitepaper.

[Whitepaper] Six API Challenges That could be Slowing your Development

Download this whitepaper to learn more.

[Whitepaper] Engaging Organized Customers in the Era of the Quadruple Aim

Explore how the pharma industry can adapt its approach to the changing healthcare marketplace in the era of the Quadruple Aim

[Whitepaper] Clinical Validation of a Powerful Immune Assay for Patient Selection

Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens.

[Whitepaper] Host Cell Protein Analysis in Biologic Drug Development

This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis.

[Whitepaper] Integrating clinical research at the Point of Care—A New Operating Model

Clinical trials take too long and cost too much—here's what needs to change.

[POCKET GUIDE] 3 Steps To Supercharge Your Literature Search

Go from Search to Full-Text Scientific Papers in a Single Click!

[Whitepaper] Achieving launch excellence in the challenging healthcare markets of today

This white paper consists of original data and expert interviews. Download it today for exclusive tools, tips and analysis on achieving launch excellence in challenging pharma markets.

[Whitepaper] Accelerate Time To Market Working With Industry Specialist MSP

With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market.

[Whitepaper] Liquid Biopsy Investor Toolkit

With the liquid biopsy market maturing and >80 companies still competing with liquid biopsy offerings, it is crucial for investors to be able to cut through the noise and identify the winners.

[Survey] Veeva 2019 Unified Clinical Operations Survey

Share your thoughts on the life sciences industry's progress in improving study execution.

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events